Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 3, pp 387–393

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines

Authors

    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Mehran Baghi
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Christoph Arnoldner
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Sotirios Bisdas
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Wolfgang Gstöttner
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Hanns Ackermann
    • Department for Biometry and Statistical AnalysisFrankfurt University Medical School
  • Angelika May
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Markus Hambek
    • ENT DepartmentFrankfurt University Medical School, University Hospital
  • Rainald Knecht
    • ENT DepartmentFrankfurt University Medical School, University Hospital
Original Paper

DOI: 10.1007/s00432-008-0477-0

Cite this article as:
Wagenblast, J., Baghi, M., Arnoldner, C. et al. J Cancer Res Clin Oncol (2009) 135: 387. doi:10.1007/s00432-008-0477-0

Abstract

Purpose

Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade®) in combination with cetuximab in squamous cell carcinoma cell lines (SCC).

Methods

Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay.

Results

Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043).

Conclusions

Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.

Keywords

BortezomibCetuximabSquamous cell carcinoma cell linesGrowth inhibitionCytotoxicity

Copyright information

© Springer-Verlag 2008